TIGRIS PHARMACEUTICALS
Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.
TIGRIS PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Bonita Springs, Florida, United States
Country:
United States
Website Url:
http://www.tigrispharma.com
Total Employee:
1+
Status:
Active
Contact:
239.444.5400
Email Addresses:
[email protected]
Total Funding:
32.49 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta LetsEncrypt SSL By Default Apache AJAX Libraries API SAKURA Internet
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Ception Therapeutics
Ception Therapeutics is a biopharmaceutical company developing novel products to address areas of unmet medical needs.
Keel Pharmaceuticals
Keel Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat type 1 diabetes and other autoimmune diseases.
Current Employees Featured
Founder
Investors List
Sonostar Capital Partners
Sonostar Capital Partners investment in Series C - Tigris Pharmaceuticals
Riverbank Capital Securities
Riverbank Capital Securities investment in Series C - Tigris Pharmaceuticals
Wexford Capital
Wexford Capital investment in Series B - Tigris Pharmaceuticals
NGN Capital
NGN Capital investment in Series B - Tigris Pharmaceuticals
Riverbank Capital Securities
Riverbank Capital Securities investment in Series B - Tigris Pharmaceuticals
Official Site Inspections
http://www.tigrispharma.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 76.223.54.146
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108